Filing Flows › Biofrontera (BFRI) › Q2 2026 › vs Q2 2025
Biofrontera (BFRI) Q2 2026 vs Q2 2025 (year over year)
Biofrontera's revenue rose $3.0M (+33%) from $9.0M in Q2 2025 to $12.0M in Q2 2026.
Biofrontera, Q2 2026: revenue $12.0M (+33% year over year), operating margin -4.4%, net loss $604K, operating cash flow −$1.7M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $12.0M | $9.0M | $3.0M | +33% |
| Net loss | $604K | $5.3M | −$4.7M | -89% |
| Costs & expenses | $12.6M | $14.4M | −$1.7M | -12% |
| Operating costs | $12.5M | $14.1M | −$1.6M | -11% |
| Interest & other, net | $57K | $224K | −$167K | -75% |
| Income tax | $23K | $21K | $2K | +10% |
| Research & development | $448K | $870K | −$422K | -49% |
| SG&A | $9.6M | $10.5M | −$900K | -9% |
| Other operating costs | $2.5M | $2.7M | −$260K | -10% |
| Operating cash sources | $2.0M | $3.3M | −$1.3M | -39% |
| Depreciation & amortization | $65K | $26K | $39K | +150% |
| Share-based compensation | $263K | $187K | $76K | +41% |
| Cash used in operations | $1.7M | $3.0M | −$1.4M | -46% |
| Net loss absorbed | $604K | $5.3M | −$4.7M | -89% |
| Working capital & other | $1.4M | −$2.1M | $3.4M | — |
Questions
How much did Biofrontera's revenue grow year over year in Q2 2026?
Biofrontera's revenue rose $3.0M (+33%) from $9.0M in Q2 2025 to $12.0M in Q2 2026.